This Campaign Has Ended.
To complete an investment that you initiated before 11:59pm on January 2nd, please click the button below or contact us for assistance: investors@fisherwallace.com.
|
Share Price: $10.94 Minimum Investment: $101.91 |
Coming in 2025
After more than two years of product development and clinical research, our Version 2.0 technology is on track to obtain FDA Clearance for the management of anxiety by Summer 2025. Our crowdfunding investors and Version 1.0 customers will be first in line to receive it.
About Fisher Wallace Labs
We validated our wearable brain stimulation technology as the most rapid self-administered treatment for anxiety and depression, with study results recently published in The Journal of Clinical Psychiatry. Created in collaboration with the teams behind Beats and Nest, OAK is designed to achieve smartphone scale.
Company Updates
- On track to submit our FDA Clearance application in Q1 2025, leveraging the successful results of our recent First Responder anxiety study (pending publication). The FDA review process will take up to 90 FDA business days.
- We are laying the groundwork for distribution through the Department of Veterans Affairs with the help of our advisor Dr. David Shulkin, the former US Secretary of Veterans Affairs, and other partners.
- Our recent clinical trial data will also be leveraged to obtain regulatory approval in Europe.
- We recently signed a 2-year agreement with BlueIO to assist us in raising venture capital and to grow our business. Among other initiatives, we intend to use venture capital to fund a 12-week depression study conducted in collaboration with Dr. Maurizio Fava, Psychiatrist-in-Chief of Massachusetts General Hospital.
No Other Wearable Works Faster
Our technology has been validated as the most rapid self-administered treatment for depression and anxiety.
Designed for New Generations
Gen Alpha and Gen Z exhibit the highest prevalence of depression and anxiety, and adopt new technology more rapidly than older generations. We are currently recruiting a children’s hospital to co-sponsor an adolescent depression study.
A Superdevice for Mental Health and Wellness
OAK is proven to treat depression and anxiety, but its ability to improve cognitive function – enabling people to think clearly – will appeal to an even broader consumer base. Our next clinical trial will measure improvements in cognitive and physical health, in addition to participants’ mood.
For Veterans and First Responders
Dr. David Shulkin, the former US Secretary of Veterans Affairs and CEO of Beth Israel Medical Center, recently joined Fisher Wallace as an advisor to help guide our VA distribution and reimbursement strategy.
The breakthrough results of our Seattle Police Department anxiety study, as well as our published depression study results, will support our efforts to gain VA adoption and help us scale treatment to the more than 4 million First Responders in the US. If you are a First Responder and would like to recommend our technology for a pilot program with your organization, please contact us.
We Proved Product-Market-Fit
Under temporary FDA clearance, Fisher Wallace commercialized its proof-of-concept Version 1.0 device and began making mental health history:
- 100K units sold
- 14K prescribers
- $40M in revenue
- Medicaid reimbursement (MaineCare)
We expect as many as 60K Version 1.0 customers to upgrade to OAK upon its commercial release.
Clear Path to Approval
We remain on a clear path to bring OAK to market next year in the US for the treatment or management of anxiety, and for the treatment of depression the following year. In Europe, we are applying for CE Marks for the treatment of anxiety and depression, using the data we’ve already obtained.
Frequently asked questions
1. Why invest in startups?
Regulation CF allows investors to invest in startups and early-growth companies. This is different from helping a company raise money on Kickstarter; with Regulation CF Offerings, you aren’t buying products or merchandise – you are buying a piece of a company and helping it grow.
2. How much can I invest?
Accredited investors can invest as much as they want. But if you are NOT an accredited investor, your investment limit depends on either your annual income or net worth, whichever is greater. If the number is less than $124,000, you can only invest 5% of it. If both are greater than $124,000 then your investment limit is 10%.
3. How do I calculate my net worth?
To calculate your net worth, just add up all of your assets and subtract all of your liabilities (excluding the value of the person’s primary residence). The resulting sum is your net worth.
4. What are the tax implications of an equity crowdfunding investment?
We cannot give tax advice, and we encourage you to talk with your accountant or tax advisor before making an investment.
5. Who can invest in a Regulation CF Offering?
Individuals over 18 years of age can invest.
6. What do I need to know about early-stage investing? Are these investments risky?
There will always be some risk involved when investing in a startup or small business. And the earlier you get in the more risk that is usually present. If a young company goes out of business, your ownership interest could lose all value. You may have limited voting power to direct the company due to dilution over time. You may also have to wait about five to seven years (if ever) for an exit via acquisition, IPO, etc. Because early-stage companies are still in the process of perfecting their products, services, and business model, nothing is guaranteed. That’s why startups should only be part of a more balanced, overall investment portfolio.
7. When will I get my investment back?
The Common Stock (the “Shares”) of Fisher Wallace Laboratories (the “Company”) are not publicly-traded. As a result, the shares cannot be easily traded or sold. As an investor in a private company, you typically look to receive a return on your investment under the following scenarios: The Company gets acquired by another company. The Company goes public (makes an initial public offering). In those instances, you receive your pro-rata share of the distributions that occur, in the case of acquisition, or you can sell your shares on an exchange. These are both considered long-term exits, taking approximately 5-10 years (and often longer) to see the possibility for an exit. It can sometimes take years to build companies. Sometimes there will not be any return, as a result of business failure.
8. Can I sell my shares?
Shares sold via Regulation Crowdfunding offerings have a one-year lockup period before those shares can be sold under certain conditions.
9. Exceptions to limitations on selling shares during the one-year lockup period:
In the event of death, divorce, or similar circumstance, shares can be transferred to:
• The company that issued the securities
• An accredited investor
• A family member (child, stepchild, grandchild, parent, stepparent, grandparent, spouse or equivalent, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships)
10. What happens if a company does not reach their funding target?
If a company does not reach their minimum funding target, all funds will be returned to the investors after the close of the offering.
11. How can I learn more about a company’s offering?
All available disclosure information can be found on the offering pages for our Regulation Crowdfunding offering.
12. What if I change my mind about investing?
You can cancel your investment at any time, for any reason, until 48 hours prior to a closing occurring. If you’ve already funded your investment and your funds are in escrow, your funds will be promptly refunded to you upon cancellation. To submit a request to cancel your investment please email: info@dealmakersecurities.com
13. How do I keep up with how the company is doing?
At a minimum, the company will be filing with the SEC and posting on it’s website an annual report, along with certified financial statements. Those should be available 120 days after the fiscal year end. If the company meets a reporting exception, or eventually has to file more reported information to the SEC, the reporting described above may end. If these reports end, you may not continually have current financial information about the company.
14. What relationship does the company have with DealMaker Securities?
Once an offering ends, the company may continue its relationship with DealMaker Securities for additional offerings in the future. DealMaker Securities’ affiliates may also provide ongoing services to the company. There is no guarantee any services will continue after the offering ends.